Grant: $267,900 - National Institutes of Health - Sep. 14, 2009
No votes have been cast for this award yet
Award Description: The objective of this administrative supplement is to examine how JAK/STAT3 pathway mediates chemopreventive properties of EGCG in vitro and KrasG12D transgenic mouse model in vivo, and assess whether inhibition of STAT3 can enhance the biological effects of EGCG and gemcitabine in pancreatic cancer. The studies proposed in this application will not only fill this gap in our knowledge but also generate data that will guide us in formulating combination-based strategies for prevention and/or treatment of human pancreatic cancer.
Project Description: The Principal Investigator, Rakesh Srivastava, Ph.D., transferred employment from The University of Texas Health Science Center at Tyler to University of Kansas Medical Center on September 18, 2009.
Jobs Summary: n/a (Total jobs reported: 0)
Project Status: Less Than 50% Completed
This award's data was last updated on Sep. 14, 2009. Help expand these official descriptions using the wiki below.